<p><strong>Mangoceuticals Inc.</strong> (NASDAQ: MGRX) 的股票在周一大幅上涨。然而，没有新闻可以解释这一波动。</p>
<p>这种势头可能与上周宣布的针对其前技术合作伙伴 <strong>Clarity Ventures</strong> 的诉讼有关，该诉讼寻求超过 7300 万美元的赔偿。</p>
<h2>诉讼详情</h2>
<p>该诉讼在德克萨斯州州法院提起，指控 Clarity 未能交付一个完全功能的、符合 HIPAA 标准的企业资源规划和电子商务平台，这对 Mangoceuticals 的运营至关重要。</p>
<p>Clarity 否认这些指控，并就未支付的发票提出反诉，Mangoceuticals 认为这些反诉是没有根据的，因为在解除合作之前已支付所有必要款项。</p>
<h2>向内部平台的转变增强了 Mangoceuticals 的运营</h2>
<p>针对与 Clarity 的问题，该公司独立开发了一个新的专有 远程医疗和电子商务平台，管理层认为这改善了客户获取和订单履行。</p>
<p>这一战略转变突显了 Mangoceuticals 在持续诉讼中增强运营表现的承诺。</p>
<p>在投诉中描述的事件之后，Mangoceuticals 表示它独立开发并部署了一个新的专有远程医疗和电子商务平台，以支持其运营。</p>
<p>该公司的当前平台是内部开发的，不依赖于 Clarity 的技术。</p>
<h2>Mangoceuticals TRT 计划凭借强劲的销售增长获得关注</h2>
<p>在二月份，Mangoceuticals 以 <strong>MangoRx</strong> 品牌销售男性健康产品，报告了其每月 99 美元的注射睾酮 替代疗法 (TRT) 计划 的势头。</p>
<p>自去年 12 月中旬推出以来，注射 TRT 计划的月销售额增长了 336%，而客户获取成本下降了 54%，公司在更新中表示。</p>
<p>管理层 预计 TRT 将成为 MangoRx 扩展注射和口服选项（包括由 Kyzatrex 提供支持的 PRIME 胶囊）的主要增长驱动力。</p>
<p>在三月份，Mangoceuticals 提交了一项专利合作条约 (PCT) 国际申请，以确保对驱动 MGX-0024 的抗病毒动物饲料和饮用水添加剂 技术 的广泛全球专利保护。</p>
<p><strong>MGRX 股票价格活动：</strong> 根据 Benzinga Pro 数据，Mangoceuticals 的股票在周一发布时上涨了 109.51%，达到 0.34 美元。</p>
<p><em>图片来源于 Shutterstock</em></p>

医疗业 ETF - SPDR

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Mangoceuticals Inc.（纳斯达克代码：MGRX）股票翻倍，上涨了 109.51%，达到 0.34 美元，尽管没有新的消息。这一激增是由于对前合作伙伴 Clarity Ventures 提起的诉讼，索赔超过 7300 万美元，指控其未能交付功能性平台。Clarity 则以未支付发票为由进行反诉。作为回应，Mangoceuticals 开发了自己的远程医疗和电子商务平台，提升了运营。此外，该公司的睾酮替代疗法（TRT）项目自推出以来销售增长了 336%，管理层预计这将推动未来的增长</p>

<p><strong>Mangoceuticals Inc.</strong> (NASDAQ: MGRX) shares are surging on Monday. However, there is no news to justify the movement.</p>
<div class="lb-trans"><p><strong>Mangoceuticals Inc.</strong> (NASDAQ: MGRX) 的股票在周一大幅上涨。然而，没有新闻可以解释这一波动。</p>
</div><p>The momentum could be due to last week’s announcement of a lawsuit seeking damages exceeding 73 million dollars against its former technology partner, <strong>Clarity Ventures</strong>.</p>
<div class="lb-trans"><p>这种势头可能与上周宣布的针对其前技术合作伙伴 <strong>Clarity Ventures</strong> 的诉讼有关，该诉讼寻求超过 7300 万美元的赔偿。</p>
</div><h2>Lawsuit Details</h2>
<div class="lb-trans"><h2>诉讼详情</h2>
</div><p>The lawsuit, filed in Texas state court, alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource planning and eCommerce platform, which was crucial for Mangoceuticals’ operations.</p>
<div class="lb-trans"><p>该诉讼在德克萨斯州州法院提起，指控 Clarity 未能交付一个完全功能的、符合 HIPAA 标准的企业资源规划和电子商务平台，这对 Mangoceuticals 的运营至关重要。</p>
</div><p>Clarity has denied these allegations and filed counterclaims regarding unpaid invoices, which Mangoceuticals asserts are unwarranted as all required payments were made before disengagement.</p>
<div class="lb-trans"><p>Clarity 否认这些指控，并就未支付的发票提出反诉，Mangoceuticals 认为这些反诉是没有根据的，因为在解除合作之前已支付所有必要款项。</p>
</div><h2>Shift To In-House Platform Strengthens Mangoceuticals Operations</h2>
<div class="lb-trans"><h2>向内部平台的转变增强了 Mangoceuticals 的运营</h2>
</div><p>In response to the issues with Clarity, the company has independently developed a new proprietary telehealth and eCommerce platform, which management believes has improved customer acquisition and order fulfillment.</p>
<div class="lb-trans"><p>针对与 Clarity 的问题，该公司独立开发了一个新的专有 远程医疗和电子商务平台，管理层认为这改善了客户获取和订单履行。</p>
</div><p>This strategic pivot highlights Mangoceuticals’ commitment to enhancing its operational performance despite ongoing litigation.</p>
<div class="lb-trans"><p>这一战略转变突显了 Mangoceuticals 在持续诉讼中增强运营表现的承诺。</p>
</div><p>Following the events described in the complaint, Mangoceuticals said it independently developed and deployed a new proprietary telehealth and e-commerce platform designed to support its operations.</p>
<div class="lb-trans"><p>在投诉中描述的事件之后，Mangoceuticals 表示它独立开发并部署了一个新的专有远程医疗和电子商务平台，以支持其运营。</p>
</div><p>The company’s current platform was developed internally and does not rely on Clarity’s technology.</p>
<div class="lb-trans"><p>该公司的当前平台是内部开发的，不依赖于 Clarity 的技术。</p>
</div><h2>Mangoceuticals TRT Program Gains Traction With Strong Sales Growth</h2>
<div class="lb-trans"><h2>Mangoceuticals TRT 计划凭借强劲的销售增长获得关注</h2>
</div><p>In February, Mangoceuticals, which sells men’s health products under the <strong>MangoRx</strong> brand, reported momentum for its $99-per-month injectable testosterone replacement therapy (TRT) program.</p>
<div class="lb-trans"><p>在二月份，Mangoceuticals 以 <strong>MangoRx</strong> 品牌销售男性健康产品，报告了其每月 99 美元的注射睾酮 替代疗法 (TRT) 计划 的势头。</p>
</div><p>Since launching in mid-December, month-over-month sales for the injectable TRT program have climbed 336%, while customer acquisition costs have fallen 54%, the company said in an update.</p>
<div class="lb-trans"><p>自去年 12 月中旬推出以来，注射 TRT 计划的月销售额增长了 336%，而客户获取成本下降了 54%，公司在更新中表示。</p>
</div><p>Management expects TRT to be the primary growth driver as MangoRx expands both injectable and oral options, including its PRIME capsule, powered by Kyzatrex.</p>
<div class="lb-trans"><p>管理层 预计 TRT 将成为 MangoRx 扩展注射和口服选项（包括由 Kyzatrex 提供支持的 PRIME 胶囊）的主要增长驱动力。</p>
</div><p>In March, Mangoceuticals filed a Patent Cooperation Treaty (PCT) international application to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024.</p>
<div class="lb-trans"><p>在三月份，Mangoceuticals 提交了一项专利合作条约 (PCT) 国际申请，以确保对驱动 MGX-0024 的抗病毒动物饲料和饮用水添加剂 技术 的广泛全球专利保护。</p>
</div><p><strong>MGRX Stock Price Activity:</strong> Mangoceuticals shares were up 109.51% at $0.34 at the time of publication on Monday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>MGRX 股票价格活动：</strong> 根据 Benzinga Pro 数据，Mangoceuticals 的股票在周一发布时上涨了 109.51%，达到 0.34 美元。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

Mangoceuticals 的股票在德克萨斯州诉讼后翻了一番